Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tamoxifen and benign breast problems.

I S Fentiman1, T J Powles

  • 1Clinical Oncology Unit, Guy's Hospital, London.

Lancet (London, England)
|November 7, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Author's reply: Lessons learned in breast cancer surgery (Br J Surg 2014; 101: 145-147).

The British journal of surgery·2014
Same author

Lessons learned in breast cancer surgery.

The British journal of surgery·2014
Same author

Why follow up breast cancer patients?

International journal of clinical practice·2013
Same author

Patterns of metastasis in women with metachronous contralateral breast cancer.

British journal of cancer·2012
Same author

Serum cotinine and prognosis in breast cancer.

Breast cancer research and treatment·2012
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Tamoxifen, used for breast cancer, may cause cataracts and liver cancer in rats due to its estrogenic effects. Further research in controlled trials is needed to evaluate its use in benign conditions.

Area of Science:

  • Oncology
  • Hepatology
  • Toxicology

Background:

  • Tamoxifen is a crucial breast cancer treatment agent.
  • It functions as an anti-estrogen but exhibits estrogenic effects on the liver.
  • High-dose tamoxifen has been linked to cataracts and hepatocellular carcinoma in rat studies.

Purpose of the Study:

  • To evaluate the risks associated with tamoxifen, particularly liver toxicity.
  • To discuss the implications of tamoxifen's estrogenic activity on its clinical applications.
  • To advocate for continued research into tamoxifen's potential benefits in benign conditions.

Main Methods:

  • Review of toxicity studies in rats concerning high-dose tamoxifen.
  • Analysis of tamoxifen's dual anti-estrogen and estrogen agonist properties.

Related Experiment Videos

  • Examination of existing data on tamoxifen-related side effects in humans.

    • Main Results:

    • High-dose tamoxifen induced cataracts and hepatocellular carcinomas in rats.
    • The observed liver tumors are attributed to tamoxifen's estrogen agonist activity.
    • Similar effects have been noted in a small number of women using oral contraceptives.

    Conclusions:

    • Concerns exist regarding tamoxifen's use in benign conditions and cancer prevention trials due to potential toxicity.
    • The development of hepatocellular carcinomas in rats is linked to estrogen agonist activity.
    • Controlled clinical trials are essential to explore new indications for tamoxifen without overlooking potential benefits.